What's Happening?
BridgeBio's drug Attruby, designed to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), has demonstrated promising results in a Phase 3 study. The study involved over 630 patients and showed that Attruby significantly reduced cardiovascular hospitalizations
by 34% compared to Pfizer's tafamidis, marketed as Vyndaqel or Vyndamax. Although Attruby also reduced the risk of all-cause mortality by 28%, this result was not statistically significant. Analysts from Jefferies have noted the potential superiority of Attruby, despite the lack of direct head-to-head studies with tafamidis. Attruby, approved in November 2024, is a transthyretin stabilizer that slows the breakdown of the transthyretin protein, which is crucial in preventing plaque formation in organs affected by ATTR-CM.
Why It's Important?
The findings from the Attruby study could significantly impact the competitive landscape of treatments for ATTR-CM, a condition that affects the heart and other organs. Pfizer's tafamidis has been a leading treatment since its approval in 2019, generating substantial revenue. However, Attruby's potential to improve survival rates and reduce hospitalizations could shift market dynamics, offering a new option for patients and potentially increasing BridgeBio's market share. This development is particularly relevant as Pfizer has secured market exclusivity for tafamidis until 2031, which could be worth up to $6 billion. The introduction of a competitive alternative like Attruby could influence pricing and accessibility of treatments for ATTR-CM.
What's Next?
BridgeBio is expected to continue its efforts to establish Attruby as a leading treatment for ATTR-CM. Further studies and direct comparisons with tafamidis may be necessary to solidify its market position. Analysts predict that Attruby could achieve over $3 billion in peak sales if it proves to be a differentiated product. Meanwhile, Pfizer's strategy to maintain market exclusivity through settlements with generic manufacturers will be crucial in protecting its revenue from tafamidis. The ongoing competition between these pharmaceutical companies will likely drive further innovation and potentially lead to more effective treatments for patients with ATTR-CM.
